Zobrazeno 1 - 10 of 53 pro vyhledávání: '"Qiao-cheng Qiu"'
2
Akademický článek
Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
Autor: Zheng Li, Jun Wang, Shuai-Shuai Ge, Qiao-Cheng Qiu, Jia-Hui Du, Shuang-Shuang Shan, Xiang-Dong Shen, Chao-Ling Wan, Bin-Ru Wang, De-Pei Wu, Hui-Ying Qiu, Sheng-Li Xue
Publikováno v: Frontiers in Oncology, Vol 12 (2022)
Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype
Externí odkaz: https://doaj.org/article/f633782528a04437a06d580daaa1350b
Zobrazit plný text záznamu
3
Akademický článek
A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
Autor: Bin-Ru Wang, Chao-Ling Wan, Song-Bai Liu, Qiao-Cheng Qiu, Tian-Mei Wu, Jun Wang, Yan-Yan Li, Shuai-Shuai Ge, Yan Qiu, Xiang-Dong Shen, Sheng-Li Xue, Zheng Li
Publikováno v: Frontiers in Oncology, Vol 11 (2021)
The management of patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) remains a challenge with few reliably effective treatments. Chidamide, a new selective HDAC inhibitor, has demonstrated some effectiveness in AML patients. Her
Externí odkaz: https://doaj.org/article/666477bf1ffb45baa59227e8b10908f1
Zobrazit plný text záznamu
8
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series
Autor: Man Qiao, Chao-Ling Wan, Shengli Xue, Jing-Ying Zou, Xiang-Dong Shen, Song-Bai Liu, Qiao-cheng Qiu, Jia Yin
Publikováno v: Leukemia & Lymphoma. 62:3300-3303
T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous hematologic disease characterized by immature lymphoid cell proliferation in the bone marrow, peripheral blood and other organs [1]. C...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e460e4c351a811df1ab4f047f27c18a
https://doi.org/10.1080/10428194.2021.1957876
Zobrazit plný text záznamu
9
[Observation of Nutritional Status Changes in Patients with Acute Leukemia During Chemotherapy]
Autor: Li-Ling, Zong, Jing, Yang, Sheng-Li, Xue, De-Pei, Wu, Xia-Ming, Zhu, Yong-Qin, Ge, Qiao-Cheng, Qiu
Publikováno v: Zhongguo shi yan xue ye xue za zhi. 30(4)
To assess changes of nutritional status by comprehensive nutrition assessment including nutritional risk screening, dietary assessment, blood biochemical index, and body composition in acute leukemia patients who had undergone chemotherapy.A total of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::079c2fd7a71784bf122d588f2145e670
https://pubmed.ncbi.nlm.nih.gov/35981358
Zobrazit plný text záznamu
10
Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
Autor: Zheng Li, Jian Zhang, Min Zhou, Jin-Li Li, Qiao-Cheng Qiu, Jian-Hong Fu, Sheng-Li Xue, Hui-Ying Qiu
Publikováno v: Oncology reports. 47(4)
Chidamide, a selective histone deacetylase inhibitor, has antitumour effects. 5‑azacitidine (5‑AZA), a hypomethylating agent, is effective in treating acute myeloid leukaemia (AML) and myelodysplastic syndrome. However, to the best of our knowled
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9117c377555293adbbcdf8015fa5bc49
https://pubmed.ncbi.nlm.nih.gov/35103292
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje